Overview

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Status:
Completed
Trial end date:
2018-03-10
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the effects of multiple-dose ramipril on the steady state pharmacokinetic (PK) parameters of sotagliflozin and its main metabolite (sotagliflozin-3-O-glucuronide) in healthy male and female subjects. Secondary Objectives: - To assess the effects of multiple-dose sotagliflozin on the PK of ramipril and its active metabolite (ramiprilat). - To assess the safety and tolerability of multiple-dose sotagliflozin with and without multiple-dose of ramipril.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi
Treatments:
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Ramipril